Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discussed complement 3 glomerulopathy (C3G) with CheckRare.

Complement 3 glomerulopathy (or C3G) is a form of membranoproliferative glomerulonephritis, an inflammatory process. It occurs when the complement system, which is a key part of the body’s defenses to fight off bacterial and viral infection, is continually engaged. When this occurs, plasma complement fragments are deposited in the glomerulus, creating inflammation and disrupting glomerular function. At this point, the clinical features of C3G are apparent, including hematuria and proteinuria.

As it is a rare disorder, it is not regularly taught during medical training, and primary care physicians will not typically see several patients with C3G. Therefore, it will not often be in the forefront of clinician’s mind when confronted with symptoms associated with C3G. Primarily a disease of the young, pediatricians may easily mistake it for other conditions, such as postinfectious (or infection-related) glomerulonephritis, which typically follows a streptococcal infection. The microscopic appearance of biopsy samples from patients with C3G may even look similar to those with postinfectious glomerulonephritis.

The VALIANT trial was a phase 3, double-blind, placebo-controlled study of the efficacy and safety of pegcetacoplan in 124 adolescent and adult patients with either C3G or the related disorder primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The primary endpoint was to determine this complement 3 inhibitor’s effect on proteinuria.

After 26 weeks of treatment, pegcetacoplan was associated with a 68% relative reduction in the urinary protein:creatinine ratio, the indicator of proteinuria, compared with the individuals receiving placebo. The study drug was not associated with a safety profile that was significantly different from that observed in the placebo group. A longer-term extension study demonstrated that the proteinuria reduction is maintained, along with kidney function, through at least 52 weeks. “Improvement in proteinuria really does herald long-term benefit,” stated Dr. Dixon. “The longer we see preservation of GFR, the more confident we are that these drugs will be effective over the long term.”

The VALIANT data support that blocking C3 has dramatic benefits by limiting complement deposition in the glomerulus in both adolescent and adults with C3G. With earlier intervention, long-term damage to kidney function may be prevented.

Dr. Dixon commented that although pegcetacoplan was effective in patients ages 12 years or greater, there is still an urgent need for treatment of younger patients, for which no effective treatment is approved. He added that since we are all born with a fixed number of glomeruli, kidney damage in young patients means their reserve of kidney function later in life will be limited. In his experience, 50% of patients with C3G will experience a halving of their kidney function within 10 years, and will need dialysis and/or a kidney transplant.

0 0

Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses complement 3 glomerulopathy (C3G) and its diagnostic challenges.

0 0

Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses the impact of Empaveli on proteinuria and kidney function in C3G.

0 0

Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses the long-term impact of Empaveli on patients with C3G.

0 0

Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses treatment gaps in C3G.

0 0

Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses the urgency of diagnosis and treatment in C3G.

0 0

🎙️ A new treatment option for adults living with recurrent respiratory papillomatosis.

The FDA has granted accelerated approval to Voceryq to reduce the need for repeated surgeries in patients with RRP.

What does this development mean for the rare disease community?

Watch this week’s The CheckRare Brief for the latest news https://checkrare.com/3d-printed-treatment-options-the-checkrare-brief/

#RareDiseaseNews #RRP #CheckRare

1 0

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.

Produced by CheckRare.

Explore additional CME activities, physician interviews, podcasts, and rare disease resources at CheckRare.com. Subscribe to the CheckRare Podcast Network for the latest rare disease education, expert interviews, and weekly news.

Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.

0 0

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.

0 0